GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Retained Earnings

Egyptian International Pharmaceutical Investments (CAI:PHAR) Retained Earnings

: E£900 Mil (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Egyptian International Pharmaceutical Investments's retained earnings for the quarter that ended in Dec. 2023 was E£900 Mil.

Egyptian International Pharmaceutical Investments's quarterly retained earnings increased from Jun. 2023 (E£588 Mil) to Sep. 2023 (E£721 Mil) and increased from Sep. 2023 (E£721 Mil) to Dec. 2023 (E£900 Mil).

Egyptian International Pharmaceutical Investments's annual retained earnings increased from Dec. 2021 (E£493 Mil) to Dec. 2022 (E£717 Mil) and increased from Dec. 2022 (E£717 Mil) to Dec. 2023 (E£900 Mil).


Egyptian International Pharmaceutical Investments Retained Earnings Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 493.30 717.13 900.19

Egyptian International Pharmaceutical Investments Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 717.13 860.07 588.26 720.98 900.19

Egyptian International Pharmaceutical Investments Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Traded in Other Exchanges
N/A
Address
1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.